These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 17414459

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK.
    J Clin Oncol; 2005 Nov 20; 23(33):8313-21. PubMed ID: 16293862
    [Abstract] [Full Text] [Related]

  • 3. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL, Cirrincione C, Aisner J, Berry DA, Allen SL, Abrams J, Chuang E, Cooper MR, Perry MC, Duggan DB, Szatrowski TP, Henderson IC, Norton L, Cancer and Leukemia Group B.
    J Clin Oncol; 2003 May 01; 21(9):1819-24. PubMed ID: 12721259
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer.
    Biron P, Durand M, Roché H, Delozier T, Battista C, Fargeot P, Spaeth D, Bachelot T, Poiget E, Monnot F, Tanguy ML, Curé H.
    Bone Marrow Transplant; 2008 Mar 01; 41(6):555-62. PubMed ID: 18037940
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group.
    J Natl Cancer Inst; 2007 Apr 04; 99(7):506-15. PubMed ID: 17405995
    [Abstract] [Full Text] [Related]

  • 9. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
    Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M, Valagussa P, Bonadonna G, European Cooperative Trial in Operable Breast Cancer Study Group.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8715-21. PubMed ID: 16361558
    [Abstract] [Full Text] [Related]

  • 10. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
    Bontenbal M, Creemers GJ, Braun HJ, de Boer AC, Janssen JT, Leys RB, Ruit JB, Goey SH, van der Velden PC, Kerkhofs LG, Schothorst KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C, Dutch Community Setting Trial for the Clinical Trial Group.
    J Clin Oncol; 2005 Oct 01; 23(28):7081-8. PubMed ID: 16192591
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S, Steger GG, Jakesz R, Tausch C, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M, Austrian Breast and Colorectal Cancer Study Group-07.
    Breast Cancer Res Treat; 2008 Nov 01; 112(2):309-16. PubMed ID: 18080748
    [Abstract] [Full Text] [Related]

  • 14. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
    Sledge GW, Hu P, Falkson G, Tormey D, Abeloff M.
    J Clin Oncol; 2000 Jan 01; 18(2):262-6. PubMed ID: 10637238
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Combination chemo-endocrine therapy of metastatic and stage IV breast cancer with cyclophosphamide, adriamycin, prednisolone and tamoxifen (CAPT)--with special reference to management of brain and liver metastasis].
    Nakamura Y, Kawaguchi M, Hata A, Watanabe H, Ueki Y, Oribe T, Koba F, Takamuku K.
    Gan To Kagaku Ryoho; 1989 Feb 01; 16(2):243-50. PubMed ID: 2919892
    [Abstract] [Full Text] [Related]

  • 18. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
    Pannuti F, Iafelice G, Martoni A, Fruet F, Angelelli B, Casadei M.
    Chemioterapia; 1984 Aug 01; 3(4):216-9. PubMed ID: 6398121
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
    Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S.
    J Clin Oncol; 2007 Feb 20; 25(6):656-61. PubMed ID: 17308269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.